Trazodone Cost in Washington (2026): Prices, Insurance, and Savings

Cash-Pay Pricing Across Washington Pharmacies

Generic trazodone ranks among the least expensive psychiatric medications available in Washington state. The average retail cash-pay price for a 30-day supply of generic trazodone (50 mg tablets) sits around $10 per month across Washington pharmacies in 2026, according to pharmacy benefit aggregator data. The manufacturer list price before any discount or insurance is approximately $40 per month.

This pricing reflects the drug's long generic history. Trazodone received FDA approval in 1981 for major depressive disorder, and multiple generic manufacturers have produced it since patent expiration. The competitive generic market keeps prices low at chains like Costco, Fred Meyer, Walmart, and independent pharmacies throughout Washington.

Prices vary by dose. The 50 mg tablet (commonly prescribed for insomnia at 25-100 mg) tends to be the cheapest formulation. The 100 mg and 150 mg tablets cost slightly more but remain under $15 per month at most Washington locations. Extended-release formulations (trazodone ER, brand Oleptro) carry significantly higher costs, often $200-400 without insurance, though prescribers rarely choose these for off-label sleep use. A 2017 analysis in the Journal of Clinical Sleep Medicine found trazodone was the most commonly prescribed medication for insomnia, partly because of this cost advantage over newer branded hypnotics.

Pharmacy discount programs (GoodRx, RxSaver, SingleCare) often reduce cash prices below $8 for a 30-day supply in the Seattle metro area. Rural Washington pharmacies may charge $12-15 without discount cards but still remain well below branded alternatives like suvorexant (Belsomra) or lemborexant (Dayvigo), which exceed $400 per month without insurance.

Washington Medicaid Coverage for Trazodone

Washington Apple Health (the state Medicaid program) covers trazodone with prior authorization. The prior authorization requirement exists primarily for utilization management, not because of safety concerns specific to the drug. Providers must document the clinical indication, which can include either the FDA-approved use for major depressive disorder or off-label insomnia treatment.

The Washington Health Care Authority (HCA) manages the preferred drug list (PDL) for Apple Health enrollees. Generic trazodone immediate-release tablets appear on the PDL as a preferred agent in the antidepressant class. Prior authorization for preferred drugs is typically straightforward: the prescriber submits the PA request electronically, and approval often comes within 24 hours for standard cases.

For off-label insomnia use specifically, Washington Medicaid may require documentation that the patient has tried sleep hygiene measures or that other covered options are inappropriate. A 2014 systematic review in the Annals of Internal Medicine evaluated the evidence for off-label insomnia medications and noted trazodone's widespread use despite limited randomized controlled trial data for that indication. Washington HCA follows similar evidentiary standards to other state Medicaid programs in acknowledging this practice pattern.

Copays for Washington Apple Health enrollees are minimal. Most adults pay $0-$3 per generic prescription. Children and pregnant individuals have no copays under federal Medicaid rules.

Insurance Coverage Beyond Medicaid

Commercial insurance plans operating in Washington (Premera Blue Cross, Regence, Kaiser Permanente, Molina, Coordinated Care) universally cover generic trazodone on their formularies. The drug sits on Tier 1 (preferred generic) for virtually all plans sold through the Washington Health Benefit Exchange and employer-sponsored coverage.

Tier 1 copays in Washington typically range from $0-$15 per 30-day fill. Many high-deductible health plans (HDHPs) apply the full cash price until the deductible is met, but because trazodone costs only $10-15 cash-pay, the out-of-pocket impact remains minimal even pre-deductible.

Medicare Part D plans covering Washington beneficiaries also include trazodone as a Tier 1 generic. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare enrollees now have a $2,000 annual out-of-pocket cap on prescription drugs, though trazodone's low cost means few patients would approach this threshold from trazodone alone. The 2023 CMS data on Part D utilization showed trazodone among the 30 most prescribed medications nationally for Medicare beneficiaries.

TRICARE (covering military families at Joint Base Lewis-McChord, Naval Station Everett, and other Washington installations) covers trazodone at the $0 copay tier when filled at military pharmacies, or $14 at retail network pharmacies for a 30-day supply.

Compounded Trazodone in Washington: Legality and Access

Compounded trazodone is legal in Washington through licensed 503A compounding pharmacies. Under FDA guidance on 503A compounding, pharmacies may prepare patient-specific compounded trazodone when a prescriber determines that a commercially available formulation does not meet the patient's needs.

Common reasons for compounded trazodone in Washington include:

• Patients who need doses not available in standard tablet strengths (e.g., 12.5 mg for elderly patients sensitive to sedation)
• Liquid formulations for patients with swallowing difficulties
• Sublingual or transdermal preparations for faster onset
• Combination preparations (e.g., trazodone with melatonin)

Washington's Board of Pharmacy regulates 503A compounding under WAC 246-945. Compounding pharmacies must hold a valid Washington state license and comply with USP 795 standards for non-sterile preparations. Several compounding pharmacies operate in the Seattle, Tacoma, Spokane, and Vancouver metro areas.

Pricing for compounded trazodone varies significantly by formulation. Simple capsule reformulations may cost $20-40 per month. Specialty formulations (sublingual troches, topical creams) range from $40-80. Insurance coverage for compounded medications is inconsistent. Most commercial plans exclude compounded drugs unless the prescriber documents medical necessity through a prior authorization or appeal process. The National Academies of Sciences report on drug compounding noted that access and quality oversight remain active areas of regulatory attention.

Telehealth Prescribing of Trazodone in Washington

Washington state permits telehealth prescribing of trazodone without restrictions. The Washington Telehealth Parity Act (RCW 48.43.735) requires insurers to cover telehealth visits at parity with in-person care. Because trazodone is non-controlled and carries no DEA scheduling requirements, prescribers face no additional telehealth barriers beyond standard prescribing practice.

Telehealth platforms operating in Washington (including HealthRX) can evaluate patients, diagnose conditions, and prescribe trazodone during audio-video visits. The prescriber must hold an active Washington medical license (MD, DO, NP, or PA). A 2020 study in Telemedicine and e-Health documented equivalent prescribing outcomes and patient satisfaction between telehealth and in-person psychiatric visits for medications like trazodone.

Washington's telehealth regulations do not require an initial in-person visit before prescribing trazodone. This differs from controlled substance rules in some states that mandate in-person evaluations. Patients in rural Eastern Washington, the San Juan Islands, or other areas with limited psychiatric access benefit particularly from this flexibility. The AAFP position on telehealth prescribing supports this approach for established, non-controlled medications.

Discount Programs and Cost-Reduction Strategies

Several discount pathways exist for Washington residents seeking the lowest trazodone cost:

Pharmacy discount cards. GoodRx, RxSaver, and SingleCare negotiate below-cash prices with participating pharmacies. In Washington, these cards reduce trazodone costs to $4-8 per month at participating locations including Costco, Walmart, and Safeway. These cards work regardless of insurance status and require no enrollment fee.

$4 generic lists. Walmart, Fred Meyer (Kroger), and some Costco locations include trazodone on their $4/month generic programs. No insurance is needed. Patients simply request the $4 pricing at the pharmacy counter.

Washington Prescription Drug Program (WPDP). The state-run WPDP provides discounts to uninsured Washington residents. Enrollment is free through the Washington Health Care Authority website. Trazodone qualifies for discounted pricing under this program.

Manufacturer savings. Because trazodone is generic-only, no manufacturer copay card exists. However, the low baseline price makes additional manufacturer assistance unnecessary for most patients.

340B pharmacies. Federally qualified health centers (FQHCs) in Washington participating in the 340B Drug Pricing Program can dispense trazodone at substantially reduced prices to eligible patients. Washington has over 30 FQHC organizations with 340B pharmacy access, concentrated in underserved areas.

A cost comparison: trazodone at $10/month compares favorably to other insomnia medications available in Washington. Zolpidem (generic Ambien) averages $15-25/month. Suvorexant (Belsomra) exceeds $400/month without insurance. Lemborexant (Dayvigo) runs $350-450/month. A 2022 pharmacoeconomic analysis in Sleep Medicine Reviews confirmed the cost-effectiveness advantage of older generic agents for chronic insomnia management.

Clinical Context: Why Providers Prescribe Trazodone for Sleep

Understanding why trazodone remains so widely prescribed explains its dominant position in Washington pharmacy claims data. The Mendelson 2005 review in the Journal of Clinical Psychiatry examined trazodone's evidence base for insomnia and noted that despite limited large-scale RCT data, the drug's serotonin-receptor antagonism, histamine H1 blockade, and alpha-1 adrenergic antagonism produce dose-dependent sedation useful for sleep initiation.

Prescribers favor trazodone for insomnia because it carries no DEA scheduling, no abuse liability classification, and no quantity limits from insurers. Unlike benzodiazepines or Z-drugs, trazodone prescriptions face no state prescription drug monitoring program (PDMP) reporting requirements in Washington. This simplifies refills and telehealth management.

Standard dosing for sleep is 25-100 mg taken 30 minutes before bedtime. The American Academy of Sleep Medicine 2017 clinical practice guideline did not strongly recommend trazodone for chronic insomnia due to limited RCT evidence, but acknowledged its widespread clinical use. A 2017 meta-analysis in Sleep Medicine Reviews found trazodone improved subjective sleep quality with modest effect sizes in the available trials.

For the FDA-approved indication of major depressive disorder, higher doses (150-400 mg daily in divided doses) are used. At these doses, sedation remains a common side effect, with the FDA-approved prescribing information listing somnolence, dizziness, and dry mouth as the most frequent adverse events.

Side Effects and Safety Considerations Relevant to Cost Decisions

Side effects influence cost decisions because they determine whether patients remain on trazodone or switch to more expensive alternatives. The most common adverse effects at sleep-promoting doses (25-100 mg) include morning sedation, dry mouth, and orthostatic hypotension. A 2020 analysis in the Journal of Clinical Psychopharmacology reported discontinuation rates of approximately 10-15% due to next-day grogginess at standard insomnia doses.

Priapism remains the most serious rare adverse effect. The FDA label carries a warning about this risk, though incidence is estimated at fewer than 1 in 10,000 patients. Washington providers should counsel male patients about this risk at initiation.

For patients who tolerate trazodone well, the $10/month cost creates strong incentive to maintain therapy rather than switching. The 2019 AASM systematic review of insomnia pharmacotherapy noted that patient willingness to continue medication correlates with both efficacy and cost burden, favoring affordable generics.

How Washington Compares to Neighboring States

Trazodone pricing in Washington falls in line with Oregon and Idaho but slightly below the national average. Oregon Medicaid (OHP) covers trazodone without prior authorization, making access marginally simpler. Idaho Medicaid also covers trazodone but requires step therapy documentation. Washington's PA requirement adds a minor administrative step that does not meaningfully delay access for most patients.

Compounding access is comparable across the Pacific Northwest. Oregon and Washington both permit 503A compounding with equivalent state-level oversight. Alaska has fewer compounding pharmacies, making access more limited for specialty formulations.

The Bureau of Labor Statistics Consumer Expenditure Survey consistently shows Pacific Northwest prescription costs running 3-7% above the national median, but generic medications like trazodone show minimal regional variation because the drugs themselves are commoditized. The real cost difference appears in dispensing fees, which Washington pharmacies set independently.